Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
Status:
Terminated
Trial end date:
2016-11-07
Target enrollment:
Participant gender:
Summary
In this phase I trial, patients with multiple myeloma will receive standard high dose
melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will
include targeted total marrow irradiation (TMI). This conventional 3+3 phase I trial will
increase the dose of TMI until the maximum tolerated dose (MTD) is reached. Initial patients
enrolled will receive the lowest possible dose of 3Gy. Maximum dose will be 12Gy.